Evidence map›Paper›PMID 40833598›Full record

ArticleCancer chemotherapy and pharmacology2025

Biotransformation and disposition of C

Tingting Cai, Dan Su, Zhiyu Tang, Jianmei Liu, Wei Tang, Yue Wu, Fan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tingting CaiDepartment of DMPK-BA, BeOne Medicines (Beijing) Co, Ltd, No.30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206, PR China.
Dan SuDepartment of DMPK-BA, BeOne Medicines (Beijing) Co, Ltd, No.30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206, PR China.
Zhiyu TangDepartment of Clinical pharmacology & Pharmacometrics, BeOne Medicines USA, Inc, Cambridge, USA.
Jianmei LiuDepartment of DMPK-BA, BeOne Medicines (Beijing) Co, Ltd, No.30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206, PR China.
Wei TangTT Consulting LLC, Washington, USA.
Yue WuDepartment of DMPK-BA, BeOne Medicines (Beijing) Co, Ltd, No.30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206, PR China.
Fan WangDepartment of DMPK-BA, BeOne Medicines (Beijing) Co, Ltd, No.30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206, PR China. fan.wang@beigene.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSonrotoclax (BGB-11417), a second-generation B-cell lymphoma-2 (BCL-2) inhibitor currently in clinical development, requires comprehensive verification of its biotransformation and disposition profiles in safety species.

methods[

resultsT

conclusionThe concordance between dog fecal metabolites and human fecal incubations underscored cross-species gut microbiome similarities. These findings offer a mechanistic insight into the fate of sonrotoclax in organisms and guide the interpretation of metabolic clearance in human.

Indexed as

Antineoplastic AgentsGastrointestinal MicrobiomeAnimalsBiotransformationCarbon RadioisotopesDogsFecesFemaleHumansMaleMiceTissue DistributionAntineoplastic AgentsCarbon-14Carbon RadioisotopesGut microbiomeMass balanceMetabolismPharmacokineticsSonrotoclax

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.